Merck and Moderna have reported positive Phase 3 clinical trial results for intismeran autogene, an investigational personalized mRNA cancer vaccine designed to help the immune system recognize and attack melanoma cells. When combined with Merck’s immunotherapy Keytruda, the treatment reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone, according to detailed results released on October 22, 2026.
The global INTerpath-001 trial enrolled 1,137 patients with high-risk melanoma that had been completely removed through surgery. After two years, 82.2% of patients receiving the vaccine combination remained free of recurrence or death, compared with 70% of patients receiving Keytruda alone. The results mark a significant milestone for personalized cancer vaccines, although the treatment remains investigational and has not yet received regulatory approval for this use.
Key Takeaways
- 42% lower risk: The vaccine combination reduced the relative risk of melanoma recurrence or death compared with Keytruda alone.
- 82.2% remained recurrence-free: The two-year recurrence-free survival rate was 82.2% with the combination, versus 70% with Keytruda alone.
- 38% lower risk of distant spread: The combination also reduced the risk of distant metastasis or death by 38%.
- Personalized treatment: The mRNA vaccine is designed around mutations identified in each patient’s tumor.
- Phase 3 milestone: INTerpath-001 is a large randomized trial showing a statistically significant benefit over Keytruda alone.
- Not yet approved: Merck and Moderna plan to engage with regulators about potential filings. Overall-survival follow-up remains ongoing.
What Did the Merck and Moderna Trial Find?
The INTerpath-001 study compared two treatment approaches for patients with high-risk, surgically removed melanoma. One group received intismeran autogene alongside Keytruda, while the control group received Keytruda alone.
The primary endpoint was recurrence-free survival, which measures the time patients remain free from cancer recurrence or death. At the prespecified interim analysis, the combination demonstrated a statistically significant improvement in this outcome.
| Trial result | Vaccine plus Keytruda | Keytruda alone |
|---|---|---|
| Patients enrolled in the overall trial | 1,137 across both groups | 1,137 across both groups |
| Recurrence-free survival at two years | 82.2% | 70.0% |
| Distant metastasis-free survival at two years | 88.5% | 80.2% |
| Relative reduction in risk of recurrence or death | 42% | Reference group |
| Relative reduction in risk of distant metastasis or death | 38% | Reference group |
Source: Merck and Moderna’s INTerpath-001 results, reported October 22, 2026. The percentages refer to trial outcomes at two years.
The findings suggest that adding the personalized vaccine to Keytruda can help more patients remain free of melanoma recurrence after surgery.
The difference in two-year recurrence-free survival was 12.2 percentage points. In practical terms, approximately 82 out of every 100 patients in the combination group remained free of recurrence or death at that point, compared with 70 out of every 100 in the Keytruda-only group.
However, the 42% figure represents a relative reduction in risk, not a 42-percentage-point improvement in survival. The companies have not yet established from this analysis that the treatment improves overall survival, an important outcome that requires continued follow-up.
How Does the Personalized mRNA Cancer Vaccine Work?
Intismeran autogene, also known as V940 or mRNA-4157, uses messenger RNA technology to help the immune system recognize features specific to an individual’s cancer.
The process begins with a sample of the patient’s tumor. Scientists analyze its genetic mutations to identify potential neoantigens—abnormal proteins or protein fragments that can distinguish cancer cells from healthy cells.
The vaccine is then designed to encode selected neoantigens from that patient’s tumor. According to the companies, the treatment can target up to 34 neoantigens.
After administration, cells use the mRNA instructions to produce the encoded antigens. The immune system can then learn to recognize these targets and generate T-cell responses directed against cancer cells carrying the relevant features.
This personalized approach differs from conventional preventive vaccines, which are designed to protect people against infectious diseases before exposure. Intismeran is a therapeutic cancer vaccine intended to help prevent cancer from returning after the primary tumor has been removed.
It also differs from a treatment designed to target one common mutation across all patients. Because tumors vary from person to person, the vaccine is customized to the genetic characteristics of each patient’s cancer.
Why Is Keytruda Combined With the Vaccine?
Keytruda, whose generic name is pembrolizumab, is an established immunotherapy that blocks the PD-1 immune checkpoint. This checkpoint can limit immune responses, allowing some cancers to evade immune attack.
By blocking PD-1, Keytruda helps immune cells maintain their ability to attack cancer. The personalized vaccine is intended to provide the immune system with additional targets to recognize.
The combination therefore brings together two different approaches: teaching the immune system which tumor-specific features to recognize and helping immune cells sustain their attack.
The Phase 3 trial tested whether this combination could improve outcomes beyond Keytruda alone in patients with high-risk melanoma following complete surgical removal. The results support the combination’s potential in this setting, although further follow-up and regulatory review are still necessary.
What the Results Mean for Melanoma Treatment
Melanoma is a potentially aggressive form of skin cancer. Even after surgery removes the visible tumor, patients with high-risk disease can experience recurrence or develop metastases in distant parts of the body.
Adjuvant treatment—therapy given after the primary cancer has been removed—is intended to reduce this risk.
Keytruda is already used in appropriate melanoma settings, but recurrence remains a concern for some patients. The new results suggest that a personalized vaccine may improve outcomes when added to existing immunotherapy.
The 38% reduction in the relative risk of distant metastasis or death is particularly relevant because distant spread can make melanoma more difficult to treat. At two years, distant metastasis-free survival was 88.5% in the combination group and 80.2% in the control group.
Nevertheless, these findings apply to the population studied: patients with high-risk, surgically removed melanoma who met the trial’s eligibility criteria. They should not be assumed to apply equally to every melanoma patient, including those with untreated, unresectable or widely metastatic disease.
What About Safety and Side Effects?
The trial did not identify new safety signals, according to Merck and Moderna. However, the combination was associated with treatment-related adverse events, and patients should not interpret the results as evidence that the therapy is risk-free.
In the reported Phase 3 data, treatment-related adverse events occurred in 95.8% of patients receiving intismeran plus Keytruda, compared with 90% of those receiving Keytruda alone. Grade 3 to 5 treatment-related adverse events occurred in 14.2% and 13.4%, respectively.
These figures show why safety and tolerability remain important alongside efficacy. Both the vaccine and the accompanying immunotherapy require medical oversight, and immune-related complications can sometimes be serious.
The companies will need to provide regulators with the complete clinical evidence, including detailed safety data, before the treatment can be considered for approval.
What Happens Next for the Cancer Vaccine?
Merck and Moderna plan to engage with regulatory authorities regarding potential submissions for intismeran autogene in combination with Keytruda. The companies have not yet established that the treatment is approved for routine clinical use.
The INTerpath-001 study will continue to evaluate other important outcomes, including overall survival. This matters because preventing recurrence and extending the time patients remain cancer-free are meaningful goals, but researchers also need to determine whether the treatment helps patients live longer.
The companies are also investigating personalized neoantigen therapy across additional cancer types, including non-small cell lung cancer, bladder cancer and renal cell carcinoma. Those programs remain separate clinical questions, and success in melanoma does not guarantee similar results elsewhere.
The next milestones will include regulatory discussions, longer-term follow-up and additional clinical evidence about the treatment’s safety and durability.
The Bigger Picture
The INTerpath-001 findings represent an important advance for personalized cancer immunotherapy. They provide Phase 3 evidence that a vaccine tailored to an individual’s tumor mutations can improve recurrence-related outcomes when added to an established immunotherapy.
The result also demonstrates the potential of mRNA technology beyond infectious-disease vaccines. Instead of using a standardized formula for a broad population, personalized cancer vaccines are designed around the molecular characteristics of an individual patient’s tumor. That approach could eventually support more targeted treatment strategies across several cancer types.
However, personalized therapies also introduce practical challenges. Tumor analysis, vaccine design and manufacturing must be coordinated for each patient, potentially affecting cost, access and the time required to deliver treatment. Regulatory approval and further evidence will be essential before the approach becomes a routine option.
FAQs
1. What is the personalized mRNA melanoma vaccine?
Intismeran autogene is an investigational mRNA-based therapeutic cancer vaccine developed by Moderna and Merck. It is designed using mutations identified in an individual patient’s tumor to help the immune system recognize cancer-specific targets.
2. How much did the vaccine reduce melanoma recurrence risk?
In the Phase 3 INTerpath-001 trial, adding the vaccine to Keytruda reduced the relative risk of recurrence or death by 42% compared with Keytruda alone. Two-year recurrence-free survival was 82.2% versus 70%.
3. Is the cancer vaccine approved for patients?
The treatment remains investigational for this use. Merck and Moderna have said they plan to engage with regulators about potential submissions. Patients should discuss approved treatment options with their oncology team.
4. Does the vaccine work without Keytruda?
The Phase 3 trial described here tested the vaccine in combination with Keytruda against Keytruda alone. These results do not establish how effective the vaccine would be on its own.
5. Could this personalized vaccine work against other cancers?
The companies are investigating related treatment approaches in other cancers, including lung, bladder and kidney cancer. Each cancer type requires its own clinical evidence, and the melanoma results do not establish effectiveness in those diseases.
Looking Ahead
The next stage for intismeran autogene will involve regulatory discussions and continued follow-up of patients in the Phase 3 trial. Longer-term data on overall survival, safety and the durability of the recurrence-free benefit will help determine the treatment’s eventual role in melanoma care.
For the broader biotechnology industry, the findings strengthen interest in personalized mRNA cancer vaccines. If the treatment gains approval and can be manufactured and delivered reliably, it could offer another option for patients at high risk of melanoma returning after surgery. For now, the results are promising clinical evidence—not a universal cure or a replacement for individualized cancer care.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
